NASDAQ:OBSV

ObsEva (OBSV) Stock Forecast, Price & News

$0.06

-0.01 (-14.29%)

(As of 09/22/2023 ET)

Compare

Today's Range: $0.06
▼
$0.08
50-Day Range: $0.04
▼
$0.10
52-Week Range: $0.08
▼
$2.14

Volume: 6,980 shs
Average Volume: 8.94 million shs
Market Capitalization: $4.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About ObsEva (NASDAQ:OBSV) Stock

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

OBSV Price History

30 days | 90 days | 365 days | Advanced Chart

OBSV Stock News Headlines

September 17, 2023 | americanbankingnews.com

ObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.com

June 18, 2023 | fool.com

ObsEva (NASDAQ: OBSV)

September 22, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

March 31, 2023 | finance.yahoo.com

ObsEva Files Year End 2022 Financial Statements

March 15, 2023 | finance.yahoo.com

ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

March 13, 2023 | markets.businessinsider.com

ObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim Chairman

March 13, 2023 | finance.yahoo.com

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

March 3, 2023 | benzinga.com

Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session

September 22, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

March 3, 2023 | investorplace.com

Why Is ObsEva (OBSV) Stock Up 93% Today?

February 24, 2023 | investorplace.com

Why ObsEva (OBSV) Stock Is Down 36% Today

February 24, 2023 | finance.yahoo.com

ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland

January 12, 2023 | uk.finance.yahoo.com

ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing

December 19, 2022 | finance.yahoo.com

ObsEva Announces Dismissal of Moratorium Proceedings

December 14, 2022 | finance.yahoo.com

ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing

December 1, 2022 | finance.yahoo.com

ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates

December 1, 2022 | finance.yahoo.com

ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

October 27, 2022 | finance.yahoo.com

ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings

October 16, 2022 | finance.yahoo.com

ObsEva SA (OBSV)

October 14, 2022 | markets.businessinsider.com

ObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of Nolasiban

October 13, 2022 | finance.yahoo.com

ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo Finance

October 13, 2022 | marketscreener.com

ObsEva Says Partner Yuyuan Bioscience Obtained Regulatory Nod for Nolasiban Drug Trial in China - Marketscreener.com

October 13, 2022 | benzinga.com

ObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China - ObsE - Benzinga

October 13, 2022 | marketscreener.com

ObsEva's Chinese Partner Wins Regulatory Nod To Launch Early-stage Trial Of Clinical Pregnancy Drug - Marketscreener.com

October 13, 2022 | globenewswire.com

ObsEva Announces IND Approval for Yuyuan Bioscience's Phase - GlobeNewswire

October 13, 2022 | finance.yahoo.com

ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

October 6, 2022 | reuters.com

OBSV.PH - Obseva SA | Stock Price & Latest News | Reuters

See More Headlines

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Company Calendar

Last Earnings: 11/04/2021
Today: 9/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OBSV
CUSIP: N/A
CIK: 1685316
Web: www.obseva.com
Phone: (122) 552-3840
Fax: N/A
Employees: 48
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,380,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -416.36%
Return on Assets: -92.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.61
Quick Ratio: 0.61

Sales & Book Value

Annual Sales: $20.11 million
Price / Sales: 0.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.41 per share
Price / Book: 0.15

Miscellaneous

Outstanding Shares: 77,971,000
Free Float: 66,743,000
Market Cap: $4.68 million
Optionable: Not Optionable
Beta: 0.68

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

William M. Brown
Chief Executive & Financial Officer

Elke Bestel
VP, Head-Drug Safety & Pharmacovigilance

Katja Buhrer
Chief Strategy Officer

Key Competitors

View All Competitors

Institutional Ownership

Simplex Trading LLC
Sold 200 shares on 8/4/2023
Ownership: 0.000%

View All Institutional Transactions

OBSV Stock - Frequently Asked Questions

How have OBSV shares performed in 2023?: ObsEva's stock was trading at $0.1450 on January 1st, 2023. Since then, OBSV shares have decreased by 58.6% and is now trading at $0.06.
View the best growth stocks for 2023 here.
How were ObsEva's earnings last quarter?: ObsEva SA (NASDAQ:OBSV) issued its quarterly earnings results on Thursday, November, 4th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.23.
What other stocks do shareholders of ObsEva own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).
When did ObsEva IPO?: (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is ObsEva's stock symbol?: ObsEva trades on the NASDAQ under the ticker symbol "OBSV."
Who are ObsEva's major shareholders?: ObsEva's stock is owned by many different institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%).
How do I buy shares of ObsEva?: Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ObsEva's stock price today?: One share of OBSV stock can currently be purchased for approximately $0.06.
How much money does ObsEva make?: ObsEva (NASDAQ:OBSV) has a market capitalization of $4.68 million and generates $20.11 million in revenue each year. The company earns $-58,380,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.
How can I contact ObsEva?: ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The official website for the company is www.obseva.com. The company can be reached via phone at (122) 552-3840 or via email at ir@obseva.ch.

This page (NASDAQ:OBSV) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial